Session » Health Services Research Poster I: Diagnosis, Management and Treatment Strategies

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 150

A Preliminary Consensus on Core Outcome Domains for Total Joint Replacement Clinical Trials: An Omeract-Based Study

9:00AM-11:00AM: Abstract Number: 133

Advocating for Rheumatoid Arthritis and Cardiovascular Health (ARCH) in a Tertiary Referral Center: A Collaborative and Systems-Based Approach to Improve Access to Care

9:00AM-11:00AM: Abstract Number: 123

An Economic Evaluation of Tofacitinib (Xeljanz) Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the US

9:00AM-11:00AM: Abstract Number: 148

An Evaluation of the Virtual Monitoring Clinic, a Novel Nurse-Led Telemonitoring Service for Monitoring Patients with Stable Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 134

Axial Spondyloarthritis: Validation of an Inter-Professional Model of Care

9:00AM-11:00AM: Abstract Number: 149

Characteristics of Patients Diagnosed with Systemic Lupus Erythematosus (SLE) Initiating Treatment with Belimumab in a US Commercially Insured Database: 2010-2014

9:00AM-11:00AM: Abstract Number: 132

Delivering a One-Stop, Integrated, Patient-Centred Service for Patients with Rheumatic Diseases. the Finnish Approach

9:00AM-11:00AM: Abstract Number: 130

Disease Activity Patterns in Incident Onset Rheumatoid Arthritis Patients in the First 3-Years of Follow up

9:00AM-11:00AM: Abstract Number: 128

Economic Burden and Treatment Patterns of Cycling Between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) Among Patients with Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 145

Economic Burden of Switching to an Anti-Tumor Necrosis Factor (anti-TNF) Versus a Non-Tumor Necrosis Factor (non-TNF) Biologic Therapy Among Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 124

Experiences with a Structured Questionnaire for Administrative Personnel to Discriminate Urgent and Non-Urgent Rheumatic Patients Referred from Primary to Secondary Care

9:00AM-11:00AM: Abstract Number: 142

Exploration of General Practioners’ Difficulties with Methotrexate and Anti-TNF Therapies in Routine Practice

9:00AM-11:00AM: Abstract Number: 147

Fatigue, Coping, Sleeping Disorders and Productivity Were Still Not Frequently Reported in Rheumatoid Arthritis Trials Published in 2014-2015: A Systematic Literature Review

9:00AM-11:00AM: Abstract Number: 143

Fiber Optic Intubation in Patients with Rheumatoid Arthritis Who Had a Surgical Procedure

9:00AM-11:00AM: Abstract Number: 131

Frequency of Lipid Testing and Management Among Rheumatoid Arthritis Patients Compared to the General Population and Patients with Diabetes

9:00AM-11:00AM: Abstract Number: 122

General Practitioners’ Perceptions of Methotrexate and Anti-TNF Therapies: A Qualitative Study

9:00AM-11:00AM: Abstract Number: 138

Identification and Documentation of Secondary Osteoarthritis in Patients with Primary Inflammatory Arthritides Using a Patient MDHAQ/RAPID3 and a Physician Estimate of Joint Damage to Recognize Patient Complexity and Inform Management Decisions

9:00AM-11:00AM: Abstract Number: 140

Identifying Psoriatic Arthritis and Ankylosing Spondylitis Patients Responsible for the Highest Costs of Care: Data from a Large US Cohort

9:00AM-11:00AM: Abstract Number: 118

Identifying the Investment Needed to Generate a Durable Prednisone Dose Decrement

9:00AM-11:00AM: Abstract Number: 125

Implementation of a Bone Health Team Markedly Improves Osteoporosis Screening, Diagnosis and Treatment Initiation Rates Compared to Standard Primary Care Practice

9:00AM-11:00AM: Abstract Number: 141

Improved Follow-up of Hypertension in Rheumatology Patients: Results of a Pilot

9:00AM-11:00AM: Abstract Number: 135

Limitations of Treat-to-Target in Rheumatoid Arthritis: Joint Damage Appears As Severe As Inflammation in Contemporary Care at One Site

9:00AM-11:00AM: Abstract Number: 113

Longitudinal, Incremental Direct Medical Costs of Giant Cell Arteritis for the First Five Years Following Diagnosis: A General Population-Based Cohort Study

9:00AM-11:00AM: Abstract Number: 139

One-Year Cost of Etanercept, Adalimumab, and Infliximab per Treated Patient with Chronic Inflammatory Arthritides in US Veterans

9:00AM-11:00AM: Abstract Number: 144

One-Year Costs Following Switching Versus Dose-Escalation Among Prevalent Tumor Necrosis Factor Inhibitors Used for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 126

Patients with Osteoarthritis and Rheumatoid Arthritis Seen at 4 Different Routine Rheumatology Care Sites at This Time Have Similar and Patient and Physician Global Estimates of Severity, and Scores for Functional Disability, Pain, and RAPID3

9:00AM-11:00AM: Abstract Number: 136

Physician Patterns of Patient Care in Systemic Lupus Erythematosus: Are We Ordering Unnecessary Tests?

9:00AM-11:00AM: Abstract Number: 127

Potential Use of Healthcare Databases for Post-Marketing Surveillance Registry: an Example Using Ustekinumab

9:00AM-11:00AM: Abstract Number: 146

Rates of Lipid Testing and Statin Prescription Filling Among U.S. Medicaid Recipients with SLE, 2007-2010

9:00AM-11:00AM: Abstract Number: 129

Rheumatologists’ Approaches to Diagnosis and Treatment of Depression

9:00AM-11:00AM: Abstract Number: 117

Same Day Rheumatology Access Clinic in an Academic Health Care Center

9:00AM-11:00AM: Abstract Number: 121

Serum Uric Acid Levels and Gout Flares in a US Managed Care Setting

9:00AM-11:00AM: Abstract Number: 114

Surfing the Net: Patient Empowerment or Patient Deceit? Fifteen-Year Trends on the World Wide Web Information for Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 116

The Effect of the Formal Approval of Colchicine on Utilization of Emergency Department and Rheumatology Outpatient Services By Patients with Gout

9:00AM-11:00AM: Abstract Number: 119

Triage in Chronic Rheumatic Diseases: Quantitative Physician Estimates for Inflammation (Reversible), Damage (Irreversible), and Distress in Patients with Rheumatoid Arthritis, Osteoarthritis, and Fibromyalgia Seen in Usual Care

9:00AM-11:00AM: Abstract Number: 115

Validation of a Large Rheumatoid Arthritis Cohort and Preventive Health Screening

9:00AM-11:00AM: Abstract Number: 120

Validity of the Inpatient Diagnosis of Systemic Lupus Erythematosus: Clarifying Hospital Readmission Rates

9:00AM-11:00AM: Abstract Number: 137

Willingness to Pay for Highly Effective Drug Treatments in Brazilian Rheumatoid Arthritis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].